Skip to main content

Table 3 Determinants of TLR among cases

From: Correlation of primary tumor metabolic parameters with clinical, histopathological and molecular characteristics in breast cancer patients at pre-operative staging FDG-PET/CT study

  TLR
Mean ±SD Median (IQR) P-value
Pathology:    =0.158#
 IDC(n=36) 3.96±3.10 2.85(3.4)
 ILC 2.41±2.98 0.80(5.3)
 Others 1  
Menopausal State   
 Pre- (n=19) 5.27±3.55 4.7 (5.1) = 0.002*
 Post- (n=21) 2.41± 1.72 1.88 (2)
Disease stage    
 I & II (n=27) 3.21±2.28 2.32(3.37) = 0.039**
 III & IV (n=13) 4.93±4.15 2.9(6.36)
ER-Receptors    
 Positive (n=31) 3.12 ±2.32 2.5 (2.97) = 0.095**
 Negative (n=9) 5.99±4.62 4.7 (7.6)
PR-Receptors    
 Positive (n=24) 3.12±2.32 2.56 (3.39) = 0.129**
 Negative (n=16) 4.74±3.81 3.25 (6.25)
Her2 neu -Receptors    
 Positive (n=14) 4.26±2.46 4 (4.23) = 0.0476*
 Negative (n=26) 3.51±3.37 2.17 (2.68)
Axillary LN Stat    
 Positive (n=27) 4.58±3.39 3.52 (5.54) = 0.022**
 Negative(n=13) 2.10±1.26 1.86 (1.96)
Tumor grade
• GI (n=5)
• GII (n=18)
• GIII (n=15)
   
GI (n=5) 1.35±0.6 1.16 (1.13) = 0.005#
GII (n=18) 3.21±2.26 2.38 (3.35)
GIII (n=15) 5.42±3.38 3.31± (6)
Molecular subtype
• Luminal A (n=10)
• Luminal B (n=19)
• Her2neuover expression (n=4)
• Basal Like (n=7)
(triple negative)
   
Luminal A (n=10) 1.96±1.6 1.45 (1.77) = 0.018#
Luminal B (n=19)
• Luminal A (n=10)
• Luminal B (n=19)
• Her2neuover expression (n=4)
• Basal Like (n=7)
(triple negative)
3.85±2.27 3 (3.66)
Her2neu-overexpression expression (n=4) 2.57±1.74 2.26 (3.25)
Triple negative (n=7) 6.9±4.82 8.12(8.29)
  1. *Independent t-test
  2. **Mann Whitney U test
  3. #Kruskal Wallis test